OCTREOTIDE ACETATE OMEGA SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

OCTREOTIDE (OCTREOTIDE ACETATE)

Saadav alates:

OMEGA LABORATORIES LIMITED

ATC kood:

H01CB02

INN (Rahvusvaheline Nimetus):

OCTREOTIDE

Annus:

100MCG

Ravimvorm:

SOLUTION

Koostis:

OCTREOTIDE (OCTREOTIDE ACETATE) 100MCG

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

1ML

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS THERAPEUTIC AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0121548001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2004-01-05

Toote omadused

1
PRODUCT MONOGRAPH
INCLUDING PATIENT
MEDICATION
INFORMATIO N
Pr
O
CTREOTIDE
A
CETATE
O
MEGA
Octreotide Injection
50 MCG / ML, 100 MCG / ML, 200 MCG / ML, 500 MCG / ML OCTREOTIDE (AS
ACETATE)
Solution
for Subcutaneous injection or intravenous infusion
Synthetic Octapeptide Analogue of Somatostatin
Omega Laboratories Limited
DATE OF INITIAL AUTHORIZATION
11,177 Hamon
February 26, 2004
Montreal, Quebec
DATE OF REVISION:
H3M 3E4
January 25, 2022
SUBMISSION CONTROL NUMBER: 252366
2
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 RECOMMENDED DOSE AND DOSAGE
ADJUSTMENT, CARCINOID TUMORS
01/2022
4 DOSAGE AND ADMINISTRATION, 4.3 RECOMMENDED DOSE AND DOSAGE
ADJUSTMENT, RECONSTITUTION, PARENTERAL PRODUCTS
01/2022
7 WARNING AND PRECAUTIONS, HEPATIC/ BILIARY / PANCREATIC
01/2022
7 WARNING AND PRECAUTIONS, MONITORING AND LABORATORY TESTS
01/2022
7 WARNING AND PRECAUTIONS, FERTILITY
01/2022
7 WARNING AND PRECAUTIONS, TERATOGENIC RISK
01/2022
7 WARNING AND PRECAUTIONS, 7.1.4 GERIATRICS
01/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.................................................................................2
TABLE OF CONTENTS
......................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................4
1.
INDICATIONS.............................................................................................................4
1.1
Pediatrics...................................................................................................................5
1.2
Geriatrics...................................................................................................................5
2.
CONTRAINDICATIONS..............................................................................................5
4.
DOSAGE AND ADMINISTRATION
....................................................................